Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | KCNT1 | Q5JUK3 | 2/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25437851 | 1.00 | EPHX2 (0.40) | EPHX2CA14NAMPTCA12RECQL | |
| SCHEMBL27870532 | 0.84 | TP53 (0.46) | CA14ALDH1A1GAALMNATP53 | |
| SCHEMBL30406525 | 0.84 | TP53 (0.46) | CA14ALDH1A1GAALMNATP53 | |
| SCHEMBL11598889 | 0.83 | RECQL (0.42) | CA14CA12RECQLALDH1A1LMNA | |
| SCHEMBL10088096 | 0.83 | RECQL (0.42) | CA14CA12RECQLALDH1A1LMNA | |
| SCHEMBL25280914 | 0.83 | L3MBTL1 (0.47) | CA14CA12CYP3A4ALDH1A1GAA | |
| SCHEMBL22345731 | 0.80 | EPHX2 (0.40) | EPHX2NAMPTPABPC1APOBEC3AEIF4H | |
| SCHEMBL22345732 | 0.80 | EPHX2 (0.40) | EPHX2NAMPTPABPC1APOBEC3AEIF4H | |
| SCHEMBL31027453 | 0.80 | EPHX2 (0.38) | EPHX2CA14CA12RECQLPABPC1 | |
| SCHEMBL25423600 | 0.79 | KMT2A (0.43) | PABPC1APOBEC3AEIF4HAPOBEC3GALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214954-A1 | METHODS OF TREATING HIV USING TRITERPENE DERIVATIVES | HETERO LABS LIMITED (IN) | 2025-07-03 | — | — | US | disclosed |
| US-12275712-B2 | Triterpene derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| EP-4248960-A2 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | Hetero Labs Limited (IN) | 2023-09-27 | — | — | EP | disclosed |
| EP-3924361-B1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LTD (IN) | 2023-09-06 | — | — | EP | disclosed |
| EP-3924361-B1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LTD (IN) | 2023-09-06 | — | — | EP | disclosed |
| US-20220177439-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2022-06-09 | — | — | US | disclosed |
| US-20220177439-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2022-06-09 | — | — | US | disclosed |
| WO-2020165741-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177439-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | CYP51A1, CCR5, HSD17B7 | EPHX2 2216/4885CA14 4630/4885NAMPT 1937/4885 |
| US-12275712-B2 | Triterpene derivatives as HIV inhibitors | CCR5, CYP51A1, CYP4A11 | EPHX2 1888/4885CA14 4611/4885NAMPT 1584/4885 |
| US-20250214954-A1 | METHODS OF TREATING HIV USING TRITERPENE DERIVATIVES | CCR5, HSD17B7, CYP51A1 | EPHX2 1776/4885CA14 3906/4885NAMPT 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.